Tilaknagar Industries Q4 FY26: Volume surges 135% to 8 mn cases, Revenue ₹949 Cr
Tilaknagar Industries reported record Q4 FY26 volumes of 8 mn cases (up 135% YoY) and FY26 volumes of 20 mn cases (up 68% YoY). Q4 revenue surged 147.5% to ₹949 Cr, and FY26 revenue grew 69.9% to ₹2,346 Cr. The company recommended a dividend of Re. 1 per share for FY26. Key targets include achieving 16-18% EBITDA margin and reducing Net Debt/EBITDA below 1.0x.
The substantial growth in key financial metrics and volumes, coupled with strategic future targets and a dividend announcement, indicates a high impact on the company's performance and investor outlook.
The company reported significant year-on-year growth in volumes, revenue, and EBITDA for both the quarter and the full fiscal year. The recommended dividend and strong future targets also contribute to a positive sentiment.
Tilaknagar Industries Limited (TI) announced its financial results for the quarter and year ended March 31, 2026. The company achieved a record volume of 8.0 million cases in Q4 FY26, marking a significant year-on-year growth of 134.7% compared to Q4 FY25. Net revenue from operations for the quarter stood at ₹949 crore, a 147.5% increase YoY. Adjusted for subsidy, net revenue grew by 154.0% to ₹941 crore. EBITDA rose by 97.1% to ₹155 crore, with an adjusted EBITDA margin of 15.5%. Profit After Tax (PAT) excluding exceptional items and amortization increased by 6.5% to ₹82 crore.
For the full fiscal year FY26, TI reported a volume of approximately 20.0 million cases, a 67.6% YoY growth. Net revenue from operations reached ₹2,346 crore, a 69.9% increase YoY. Adjusted for subsidy, net revenue was ₹2,279 crore, growing at 68.6%. EBITDA for FY26 grew by 64.5% to ₹419 crore, and adjusted EBITDA margin was 15.5%. PAT, excluding exceptional items and amortization, increased by 30.3% to ₹299 crore.
The Board of Directors has recommended a dividend of Re. 1 per equity share for FY 2025-26. Mr. Amit Dahanukar, Chairman & Managing Director, highlighted the achievement of ~20 million cases in FY26, with Mansion House Brandy reaching a record 10 million cases. He outlined immediate targets for the next three years, including double-digit volume growth, achieving an EBITDA margin of 16-18%, reducing Net Debt/EBITDA below 1.0x, and expanding the luxury and premium portfolio. The company has also exited the Transition Services & Manufacturing Agreement for approximately 75% of the Imperial Blue business, taking over manufacturing operations in those states.
What to do with a filing like this
Tilaknagar Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tilaknagar Industries Limited. Read the original for the full detail.